Stay updated on Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.4.3, replacing Revision: v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-11T23:31:22.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added to the page; the funding-status notice about a lapse in government funding and the previous Revision: v3.4.1 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-02-11T14:20:42.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    - The page now displays a site-wide notice about government funding status and NIH Clinical Center operations, and the revision has been updated from v3.4.0 to v3.4.1.
    Difference
    0.2%
    Check dated 2026-02-04T10:26:00.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    New glossary display, a new 'Last Update Submitted that Met QC Criteria' label, 'No FEAR Act Data' label, and a site revision note 'Revision: v3.4.0', with capitalization changes such as 'Last Update Submitted that met QC Criteria' and 'No FEAR Act data'. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-28T06:20:38.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    A minor revision update was applied: Revision: v3.3.4 replacing v3.3.3. This metadata change does not affect the study details, eligibility criteria, endpoints, or user-facing content on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T02:40:24.000Z thumbnail image
  8. Check
    82 days ago
    Change Detected
    Summary
    Expanded the study locations by adding numerous site locations across the US, Argentina, Australia, and Europe, broadening enrollment options. Removed the HHS Vulnerability Disclosure entry and several location groups.
    Difference
    4%
    Check dated 2025-12-23T21:57:39.000Z thumbnail image

Stay in the know with updates to Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page.